| Mrs Stephanie Ann Dent, DNP, ARNP, FNP-C | |
|
968 Kanakea Loop, Lahaina, HI 96761-1320 | |
| (808) 281-0255 | |
| Not Available |
| Full Name | Mrs Stephanie Ann Dent |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 968 Kanakea Loop, Lahaina, Hawaii |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013579416 | NPI | - | NPPES |
| 2136421 | Medicaid | WA | |
| 2086163 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | AP60974085 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Stephanie Ann Dent, DNP, ARNP, FNP-C 968 Kanakea Loop, Lahaina, HI 96761-1320 Ph: () - | Mrs Stephanie Ann Dent, DNP, ARNP, FNP-C 968 Kanakea Loop, Lahaina, HI 96761-1320 Ph: (808) 281-0255 |
News Archive
Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.
Researchers have called on European policymakers to make adequate resources available to tackle pancreatic cancer, a disease that is almost invariably fatal and where little progress has been made over the past 40 years.
Today, The U.S. Conference of Mayors (USCM) congratulates the U.S. Senate on taking an important step forward to provide health care for millions of the uninsured. In a historic Christmas Eve session, by a vote of 60-39, the Senate passed the Patient Protection and Affordable Care Act.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) amendment to conduct a Phase II clinical trial in the U.S. of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).
California Healthcare Institute today submitted formal comments to the U.S. Food and Drug Administration (FDA) regarding the Center for Devices and Radiological Health 510(k) Working Group Preliminary Report and Recommendations, which could transform the 510(k) regulatory process for new medical devices, greatly affecting innovation and public health in California. CHI is a non-profit public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.
› Verified 8 days ago
Mrs. Lindsey Elizabeth Kauimalula Guth, CPNP-PC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 871 Lahainaluna Rd, Lahaina, HI 96761 Phone: 808-694-0820 | |
Dr. Rachel Alexandra Graham, DNP, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 305 Keawe St Ste 507, Lahaina, HI 96761 Phone: 808-667-6161 | |
Mrs. Carrie R Baker, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 727 Wainee St Ste 201, Lahaina, HI 96761 Phone: 808-280-4192 Fax: 877-273-2946 |